APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucose Dependent Insulinotropic Receptor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Glucose Dependent Insulinotropic Receptor Market Analysis and Forecast 2026-2032

19 December 2025191 pages

Choose your research edition.

Industry ResearchGlucose Dependent Insulinotropic Receptor Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucose Dependent Insulinotropic Receptor Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Glucose Dependent Insulinotropic Receptor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucose Dependent Insulinotropic Receptor Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucose Dependent Insulinotropic Receptor Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Glucose Dependent Insulinotropic Receptor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Glucose Dependent Insulinotropic Receptor include Takeda Pharmaceutical Co Ltd, Novartis AG, Merck & Co Inc, GlaxoSmithKline Plc, Amgen Inc, Yuhan Corp, Taisho Pharmaceutical Holdings Co Ltd, Kowa Co Ltd and Hyundai Pharmaceutical Co Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Glucose Dependent Insulinotropic Receptor, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Glucose Dependent Insulinotropic Receptor, also provides the revenue of main regions and countries. Of the upcoming market potential for Glucose Dependent Insulinotropic Receptor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Glucose Dependent Insulinotropic Receptor revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Glucose Dependent Insulinotropic Receptor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Glucose Dependent Insulinotropic Receptor revenue, projected growth trends, production technology, application and end-user industry.

Glucose Dependent Insulinotropic Receptor Segment by Company

Takeda Pharmaceutical Co Ltd

Novartis AG

Merck & Co Inc

GlaxoSmithKline Plc

Amgen Inc

Yuhan Corp

Taisho Pharmaceutical Holdings Co Ltd

Kowa Co Ltd

Hyundai Pharmaceutical Co Ltd

F. Hoffmann-La Roche Ltd

Dong-A Socio Holdings Co Ltd

CymaBay Therapeutics Inc

Arena Pharmaceuticals Inc

Glucose Dependent Insulinotropic Receptor Segment by Type

MBX-2982

HOB-047

HD-0471953

HD-0471042

GSK-2041706

DA-1241

Others

Glucose Dependent Insulinotropic Receptor Segment by Application

Type 2 Diabetes

Obesity

Chronic Obstructive Pulmonary Disease (COPD)

Dyslipidemia

Others

Glucose Dependent Insulinotropic Receptor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucose Dependent Insulinotropic Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucose Dependent Insulinotropic Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucose Dependent Insulinotropic Receptor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Glucose Dependent Insulinotropic Receptor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Glucose Dependent Insulinotropic Receptor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glucose Dependent Insulinotropic Receptor revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Glucose Dependent Insulinotropic Receptor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. MBX-2982 Major Player Table 3. HOB-047 Major Player Table 4. HD-0471953 Major Player Table 5. HD-0471042 Major Player Table 6. GSK-2041706 Major Player Table 7. DA-1241 Major Player Table 8. Others Major Player Table 9. Global Glucose Dependent Insulinotropic Receptor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Type 2 Diabetes Major Player Table 11. Obesity Major Player Table 12. Chronic Obstructive Pulmonary Disease (COPD) Major Player Table 13. Dyslipidemia Major Player Table 14. Others Major Player Table 15. Glucose Dependent Insulinotropic Receptor Industry Trends Table 16. Glucose Dependent Insulinotropic Receptor Industry Drivers Table 17. Glucose Dependent Insulinotropic Receptor Industry Opportunities and Challenges Table 18. Glucose Dependent Insulinotropic Receptor Industry Restraints Table 19. Global Glucose Dependent Insulinotropic Receptor Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 20. Global Glucose Dependent Insulinotropic Receptor Market Size by Region (2021-2026) & (US$ Million) Table 21. Global Glucose Dependent Insulinotropic Receptor Market Share by Region (2021-2026) Table 22. Global Glucose Dependent Insulinotropic Receptor Market Size by Region (2027-2032) & (US$ Million) Table 23. Global Glucose Dependent Insulinotropic Receptor Market Share by Region (2027-2032) Table 24. Global Glucose Dependent Insulinotropic Receptor Revenue by Players (US$ Million) & (2021-2026) Table 25. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Players (2021-2026) Table 26. Global Glucose Dependent Insulinotropic Receptor Key Players Ranking, 2024 VS 2025 VS 2026 Table 27. Global Glucose Dependent Insulinotropic Receptor Key Players Headquarters & Area Served Table 28. Global Glucose Dependent Insulinotropic Receptor Players, Product Type & Application Table 29. Global Glucose Dependent Insulinotropic Receptor Players Establishment Date Table 30. Global Players Market Concentration Ratio (CR5 and HHI) Table 31. Global Glucose Dependent Insulinotropic Receptor by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Glucose Dependent Insulinotropic Receptor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Type (2021-2026) Table 36. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Type (2027-2032) Table 37. Global Glucose Dependent Insulinotropic Receptor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026) & (US$ Million) Table 39. Global Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032) & (US$ Million) Table 40. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Application (2021-2026) Table 41. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Application (2027-2032) Table 42. Takeda Pharmaceutical Co Ltd Company Information Table 43. Takeda Pharmaceutical Co Ltd Business Overview Table 44. Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 46. Takeda Pharmaceutical Co Ltd Recent Development Table 47. Novartis AG Company Information Table 48. Novartis AG Business Overview Table 49. Novartis AG Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Novartis AG Glucose Dependent Insulinotropic Receptor Product Portfolio Table 51. Novartis AG Recent Development Table 52. Merck & Co Inc Company Information Table 53. Merck & Co Inc Business Overview Table 54. Merck & Co Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Merck & Co Inc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 56. Merck & Co Inc Recent Development Table 57. GlaxoSmithKline Plc Company Information Table 58. GlaxoSmithKline Plc Business Overview Table 59. GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 61. GlaxoSmithKline Plc Recent Development Table 62. Amgen Inc Company Information Table 63. Amgen Inc Business Overview Table 64. Amgen Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Amgen Inc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 66. Amgen Inc Recent Development Table 67. Yuhan Corp Company Information Table 68. Yuhan Corp Business Overview Table 69. Yuhan Corp Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Yuhan Corp Glucose Dependent Insulinotropic Receptor Product Portfolio Table 71. Yuhan Corp Recent Development Table 72. Taisho Pharmaceutical Holdings Co Ltd Company Information Table 73. Taisho Pharmaceutical Holdings Co Ltd Business Overview Table 74. Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 76. Taisho Pharmaceutical Holdings Co Ltd Recent Development Table 77. Kowa Co Ltd Company Information Table 78. Kowa Co Ltd Business Overview Table 79. Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 81. Kowa Co Ltd Recent Development Table 82. Hyundai Pharmaceutical Co Ltd Company Information Table 83. Hyundai Pharmaceutical Co Ltd Business Overview Table 84. Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 86. Hyundai Pharmaceutical Co Ltd Recent Development Table 87. F. Hoffmann-La Roche Ltd Company Information Table 88. F. Hoffmann-La Roche Ltd Business Overview Table 89. F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 91. F. Hoffmann-La Roche Ltd Recent Development Table 92. Dong-A Socio Holdings Co Ltd Company Information Table 93. Dong-A Socio Holdings Co Ltd Business Overview Table 94. Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 96. Dong-A Socio Holdings Co Ltd Recent Development Table 97. CymaBay Therapeutics Inc Company Information Table 98. CymaBay Therapeutics Inc Business Overview Table 99. CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 101. CymaBay Therapeutics Inc Recent Development Table 102. Arena Pharmaceuticals Inc Company Information Table 103. Arena Pharmaceuticals Inc Business Overview Table 104. Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 106. Arena Pharmaceuticals Inc Recent Development Table 107. North America Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026) & (US$ Million) Table 110. North America Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032) & (US$ Million) Table 111. North America Glucose Dependent Insulinotropic Receptor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. North America Glucose Dependent Insulinotropic Receptor Revenue by Country (2021-2026) & (US$ Million) Table 113. North America Glucose Dependent Insulinotropic Receptor Revenue by Country (US$ Million) & (2027-2032) Table 114. Europe Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026) & (US$ Million) Table 115. Europe Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032) & (US$ Million) Table 116. Europe Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026) & (US$ Million) Table 117. Europe Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032) & (US$ Million) Table 118. Europe Glucose Dependent Insulinotropic Receptor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Europe Glucose Dependent Insulinotropic Receptor Revenue by Country (2021-2026) & (US$ Million) Table 120. Europe Glucose Dependent Insulinotropic Receptor Revenue by Country (US$ Million) & (2027-2032) Table 121. China Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026) & (US$ Million) Table 122. China Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032) & (US$ Million) Table 123. China Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026) & (US$ Million) Table 124. China Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026) & (US$ Million) Table 126. Asia Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032) & (US$ Million) Table 127. Asia Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026) & (US$ Million) Table 128. Asia Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Glucose Dependent Insulinotropic Receptor Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 130. Asia Glucose Dependent Insulinotropic Receptor Revenue by Region (US$ Million) & (2021-2026) Table 131. Asia Glucose Dependent Insulinotropic Receptor Revenue by Region (US$ Million) & (2027-2032) Table 132. SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026) & (US$ Million) Table 133. SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032) & (US$ Million) Table 134. SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026) & (US$ Million) Table 135. SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032) & (US$ Million) Table 136. SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Country (2021-2026) & (US$ Million) Table 138. SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Country (US$ Million) & (2027-2032) Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Glucose Dependent Insulinotropic Receptor Image Figure 2. Global Glucose Dependent Insulinotropic Receptor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucose Dependent Insulinotropic Receptor Market Size Share 2021 VS 2025 VS 2032 Figure 4. MBX-2982 Image Figure 5. HOB-047 Image Figure 6. HD-0471953 Image Figure 7. HD-0471042 Image Figure 8. GSK-2041706 Image Figure 9. DA-1241 Image Figure 10. Others Image Figure 11. Global Glucose Dependent Insulinotropic Receptor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Glucose Dependent Insulinotropic Receptor Market Size Share 2021 VS 2025 VS 2032 Figure 13. Type 2 Diabetes Image Figure 14. Obesity Image Figure 15. Chronic Obstructive Pulmonary Disease (COPD) Image Figure 16. Dyslipidemia Image Figure 17. Others Image Figure 18. Global Glucose Dependent Insulinotropic Receptor Market Size (US$ Million) & (2021-2032) Figure 19. Global Glucose Dependent Insulinotropic Receptor Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 20. Global Glucose Dependent Insulinotropic Receptor Market Share by Region: 2021 VS 2025 VS 2032 Figure 21. Global Glucose Dependent Insulinotropic Receptor Players Revenue Share Top 10 and Top 5 in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Glucose Dependent Insulinotropic Receptor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Type (2021-2032) Figure 26. Global Glucose Dependent Insulinotropic Receptor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 28. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Application (2021-2032) Figure 29. North America Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. North America Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032) Figure 31. North America Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032) Figure 32. North America Glucose Dependent Insulinotropic Receptor Revenue Share by Country (2021-2032) Figure 33. United States Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Canada Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Mexico Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Europe Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 37. Europe Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032) Figure 38. Europe Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032) Figure 39. Europe Glucose Dependent Insulinotropic Receptor Revenue Share by Country (2021-2032) Figure 40. Germany Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. France Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. U.K. Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Italy Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Spain Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Russia Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Netherlands Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. Nordic Countries Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. China Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. China Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032) Figure 50. China Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032) Figure 51. Asia Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 52. Asia Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032) Figure 53. Asia Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032) Figure 54. Asia Glucose Dependent Insulinotropic Receptor Revenue Share by Region (2021-2032) Figure 55. Japan Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. South Korea Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. India Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Australia Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Taiwan Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Southeast Asia Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. SAMEA Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 62. SAMEA Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032) Figure 63. SAMEA Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032) Figure 64. SAMEA Glucose Dependent Insulinotropic Receptor Revenue Share by Country (2021-2032) Figure 65. Brazil Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Argentina Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Chile Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Colombia Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Peru Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Saudi Arabia Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Israel Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. UAE Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Turkey Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Iran Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Egypt Glucose Dependent Insulinotropic Receptor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • MBX-2982
  • HOB-047
  • HD-0471953
  • HD-0471042
  • GSK-2041706
  • DA-1241
  • Others
Applications
  • Type 2 Diabetes
  • Obesity
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Dyslipidemia
  • Others
Companies covered
  • Takeda Pharmaceutical Co Ltd
  • Novartis AG
  • Merck & Co Inc
  • GlaxoSmithKline Plc
  • Amgen Inc
  • Yuhan Corp
  • Taisho Pharmaceutical Holdings Co Ltd
  • Kowa Co Ltd
  • Hyundai Pharmaceutical Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Dong-A Socio Holdings Co Ltd
  • CymaBay Therapeutics Inc
  • Arena Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Glucose Dependent Insulinotropic Receptor Market by Type
  3. 1.2.1 Global Glucose Dependent Insulinotropic Receptor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 MBX-2982
  5. 1.2.3 HOB-047
  6. 1.2.4 HD-0471953
  7. 1.2.5 HD-0471042
  8. 1.2.6 GSK-2041706
  9. 1.2.7 DA-1241
  10. 1.2.8 Others
  11. 1.3 Glucose Dependent Insulinotropic Receptor Market by Application
  12. 1.3.1 Global Glucose Dependent Insulinotropic Receptor Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Type 2 Diabetes
  14. 1.3.3 Obesity
  15. 1.3.4 Chronic Obstructive Pulmonary Disease (COPD)
  16. 1.3.5 Dyslipidemia
  17. 1.3.6 Others
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Glucose Dependent Insulinotropic Receptor Market Dynamics
  1. 2.1 Glucose Dependent Insulinotropic Receptor Industry Trends
  2. 2.2 Glucose Dependent Insulinotropic Receptor Industry Drivers
  3. 2.3 Glucose Dependent Insulinotropic Receptor Industry Opportunities and Challenges
  4. 2.4 Glucose Dependent Insulinotropic Receptor Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Glucose Dependent Insulinotropic Receptor Market Perspective (2021-2032)
  2. 3.2 Global Glucose Dependent Insulinotropic Receptor Growth Trends by Region
  3. 3.2.1 Global Glucose Dependent Insulinotropic Receptor Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Glucose Dependent Insulinotropic Receptor Market Size by Region (2021-2026)
  5. 3.2.3 Global Glucose Dependent Insulinotropic Receptor Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Glucose Dependent Insulinotropic Receptor Revenue by Players
  2. 4.1.1 Global Glucose Dependent Insulinotropic Receptor Revenue by Players (2021-2026)
  3. 4.1.2 Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Glucose Dependent Insulinotropic Receptor Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Glucose Dependent Insulinotropic Receptor Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Glucose Dependent Insulinotropic Receptor Key Players Headquarters & Area Served
  7. 4.4 Global Glucose Dependent Insulinotropic Receptor Players, Product Type & Application
  8. 4.5 Global Glucose Dependent Insulinotropic Receptor Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Glucose Dependent Insulinotropic Receptor Market CR5 and HHI
  11. 4.6.3 2025 Glucose Dependent Insulinotropic Receptor Tier 1, Tier 2, and Tier 3
5 Glucose Dependent Insulinotropic Receptor Market Size by Type
  1. 5.1 Global Glucose Dependent Insulinotropic Receptor Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2032)
  3. 5.3 Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Type (2021-2032)
6 Glucose Dependent Insulinotropic Receptor Market Size by Application
  1. 6.1 Global Glucose Dependent Insulinotropic Receptor Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2032)
  3. 6.3 Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Co Ltd
  2. 7.1.1 Takeda Pharmaceutical Co Ltd Company Information
  3. 7.1.2 Takeda Pharmaceutical Co Ltd Business Overview
  4. 7.1.3 Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Glucose Dependent Insulinotropic Receptor Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Merck & Co Inc
  14. 7.3.1 Merck & Co Inc Company Information
  15. 7.3.2 Merck & Co Inc Business Overview
  16. 7.3.3 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
  18. 7.3.5 Merck & Co Inc Recent Developments
  19. 7.4 GlaxoSmithKline Plc
  20. 7.4.1 GlaxoSmithKline Plc Company Information
  21. 7.4.2 GlaxoSmithKline Plc Business Overview
  22. 7.4.3 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Product Portfolio
  24. 7.4.5 GlaxoSmithKline Plc Recent Developments
  25. 7.5 Amgen Inc
  26. 7.5.1 Amgen Inc Company Information
  27. 7.5.2 Amgen Inc Business Overview
  28. 7.5.3 Amgen Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Amgen Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
  30. 7.5.5 Amgen Inc Recent Developments
  31. 7.6 Yuhan Corp
  32. 7.6.1 Yuhan Corp Company Information
  33. 7.6.2 Yuhan Corp Business Overview
  34. 7.6.3 Yuhan Corp Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Yuhan Corp Glucose Dependent Insulinotropic Receptor Product Portfolio
  36. 7.6.5 Yuhan Corp Recent Developments
  37. 7.7 Taisho Pharmaceutical Holdings Co Ltd
  38. 7.7.1 Taisho Pharmaceutical Holdings Co Ltd Company Information
  39. 7.7.2 Taisho Pharmaceutical Holdings Co Ltd Business Overview
  40. 7.7.3 Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  42. 7.7.5 Taisho Pharmaceutical Holdings Co Ltd Recent Developments
  43. 7.8 Kowa Co Ltd
  44. 7.8.1 Kowa Co Ltd Company Information
  45. 7.8.2 Kowa Co Ltd Business Overview
  46. 7.8.3 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  48. 7.8.5 Kowa Co Ltd Recent Developments
  49. 7.9 Hyundai Pharmaceutical Co Ltd
  50. 7.9.1 Hyundai Pharmaceutical Co Ltd Company Information
  51. 7.9.2 Hyundai Pharmaceutical Co Ltd Business Overview
  52. 7.9.3 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  54. 7.9.5 Hyundai Pharmaceutical Co Ltd Recent Developments
  55. 7.10 F. Hoffmann-La Roche Ltd
  56. 7.10.1 F. Hoffmann-La Roche Ltd Company Information
  57. 7.10.2 F. Hoffmann-La Roche Ltd Business Overview
  58. 7.10.3 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  59. 7.10.4 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  60. 7.10.5 F. Hoffmann-La Roche Ltd Recent Developments
  61. 7.11 Dong-A Socio Holdings Co Ltd
  62. 7.11.1 Dong-A Socio Holdings Co Ltd Company Information
  63. 7.11.2 Dong-A Socio Holdings Co Ltd Business Overview
  64. 7.11.3 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  66. 7.11.5 Dong-A Socio Holdings Co Ltd Recent Developments
  67. 7.12 CymaBay Therapeutics Inc
  68. 7.12.1 CymaBay Therapeutics Inc Company Information
  69. 7.12.2 CymaBay Therapeutics Inc Business Overview
  70. 7.12.3 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  71. 7.12.4 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
  72. 7.12.5 CymaBay Therapeutics Inc Recent Developments
  73. 7.13 Arena Pharmaceuticals Inc
  74. 7.13.1 Arena Pharmaceuticals Inc Company Information
  75. 7.13.2 Arena Pharmaceuticals Inc Business Overview
  76. 7.13.3 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
  78. 7.13.5 Arena Pharmaceuticals Inc Recent Developments
8 North America
  1. 8.1 North America Glucose Dependent Insulinotropic Receptor Revenue (2021-2032)
  2. 8.2 North America Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2032)
  3. 8.2.1 North America Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026)
  4. 8.2.2 North America Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032)
  5. 8.3 North America Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032)
  6. 8.4 North America Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2032)
  7. 8.4.1 North America Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026)
  8. 8.4.2 North America Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032)
  9. 8.5 North America Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032)
  10. 8.6 North America Glucose Dependent Insulinotropic Receptor Revenue by Country
  11. 8.6.1 North America Glucose Dependent Insulinotropic Receptor Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Glucose Dependent Insulinotropic Receptor Revenue by Country (2021-2026)
  13. 8.6.3 North America Glucose Dependent Insulinotropic Receptor Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Glucose Dependent Insulinotropic Receptor Revenue (2021-2032)
  2. 9.2 Europe Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2032)
  3. 9.2.1 Europe Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026)
  4. 9.2.2 Europe Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032)
  5. 9.3 Europe Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032)
  6. 9.4 Europe Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2032)
  7. 9.4.1 Europe Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026)
  8. 9.4.2 Europe Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032)
  9. 9.5 Europe Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032)
  10. 9.6 Europe Glucose Dependent Insulinotropic Receptor Revenue by Country
  11. 9.6.1 Europe Glucose Dependent Insulinotropic Receptor Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Glucose Dependent Insulinotropic Receptor Revenue by Country (2021-2026)
  13. 9.6.3 Europe Glucose Dependent Insulinotropic Receptor Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Glucose Dependent Insulinotropic Receptor Revenue (2021-2032)
  2. 10.2 China Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2032)
  3. 10.2.1 China Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026)
  4. 10.2.2 China Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032)
  5. 10.3 China Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032)
  6. 10.4 China Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2032)
  7. 10.4.1 China Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026)
  8. 10.4.2 China Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032)
  9. 10.5 China Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Glucose Dependent Insulinotropic Receptor Revenue (2021-2032)
  2. 11.2 Asia Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2032)
  3. 11.2.1 Asia Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026)
  4. 11.2.2 Asia Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032)
  5. 11.3 Asia Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032)
  6. 11.4 Asia Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2032)
  7. 11.4.1 Asia Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026)
  8. 11.4.2 Asia Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032)
  9. 11.5 Asia Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032)
  10. 11.6 Asia Glucose Dependent Insulinotropic Receptor Revenue by Country
  11. 11.6.1 Asia Glucose Dependent Insulinotropic Receptor Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Glucose Dependent Insulinotropic Receptor Revenue by Country (2021-2026)
  13. 11.6.3 Asia Glucose Dependent Insulinotropic Receptor Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Glucose Dependent Insulinotropic Receptor Revenue (2021-2032)
  2. 12.2 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Type (2027-2032)
  5. 12.3 SAMEA Glucose Dependent Insulinotropic Receptor Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Application (2027-2032)
  9. 12.5 SAMEA Glucose Dependent Insulinotropic Receptor Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Country
  11. 12.6.1 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Glucose Dependent Insulinotropic Receptor Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst